Healthcare Industry News: Parkinson's disease
News Release - April 17, 2007
Integra LifeSciences Releases New Brain Mapping Software to Treat Parkinson's DiseaseSoftware Enhances Accuracy and Safety in Movement Disorder Surgeries
PLAINSBORO, N.J., April 17, 2007 (Healthcare Sales & Marketing Network) -- Integra LifeSciences Holdings Corporation (NasdaqGS:IART ) announced today that its subsidiary, Integra Radionics, released a major upgrade for the NeuroSight(R) Arc module of the OmniSight(R) EXcel image-guided system. Developed in collaboration with leading neurosurgeons worldwide, NeuroSight(R) Arc maps the trajectories and targets used for treatment of functional neurological disorders including Parkinson's disease and other movement disorders.
``The latest system from Integra Radionics allows me to quickly and accurately visualize and plan tumor and functional neurosurgery procedures,'' said Dr. James Schumacher, a leading Parkinson's surgeon from Sarasota, FL. ``I search for the most accurate, reliable and safe equipment for my patients, and this is the best system for functional neurosurgery on the market.''
The software contains digital brain maps that are overlaid with the patient scans to guide the neurosurgical procedures. The new version improves this alignment with more patient-specific adjustments. It also enhances the resolution of the computed tomography (CT) and magnetic resonance imaging (MRI) patient scans used for targeting, increases compatibility with the Integra Radionics industry leading CRW(R) stereotactic system, and adds several advancements in the graphical user interface for superior ease-of-use planning.
``The new software offers neurosurgeons improved planning capability for even more accurate and safer treatments,'' noted Jason Ellnor, Integra Radionic's Director of Marketing for the stereotactic product line. ``This continues our goal of developing trusted tools with and for the neurosurgeon.''
Worldwide prevalence of movement disorders is estimated at over four million people, and demand is increasing for effective therapies to delay disease progression and improve patient's lives. When medication is ineffective, severe movement disorders may respond to Deep Brain Surgery (DBS), which places precisely located implantable electrodes within the brain to deliver electrical impulses to counteract the tremors. The electrodes are connected to a neurostimulator, or ``pacemaker,'' which is implanted under the patient's collarbone. The worldwide movement disorders therapeutics market is currently estimated at over $2 billion and is expected to reach approximately $4 billion by 2009.
The surgery to place the electrode in the brain involves high definition diagnostic images of each patient, usually through the use of MRI and CT scans. These images are then transferred to the OmniSight(R) EXcel image-guided surgery system for pre-surgical planning, which produces exact coordinates of the target for the CRW(R) stereotactic system. The CRW(R) system is a medical device which allows for very precise targeting and placement of the electrode within the brain. The CRW(R) platform has been used in over 250,000 procedures worldwide for the precise placement of biopsy needles and surgical electrodes in the brain.
Over 750 institutions worldwide use Integra Radionics computer-assisted surgery systems for brain biopsies, tumor resections, spinal implantations, and functional neurosurgery.
Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is dedicated to improving the quality of life for patients through the development, manufacturing, and marketing of cost-effective surgical implants and medical instruments. Our products, used primarily in neurosurgery, extremity reconstruction, orthopedics and general surgery, are used to treat millions of patients every year. Integra's headquarters are in Plainsboro, New Jersey, and we have research and manufacturing facilities throughout the world. Please visit our website at http://www.Integra-LS.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the future use of the OmniSight(R) EXcel image-guided surgery system and CRW(R) stereotactic system . Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use these products may affect the prospects for their use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the Risk Factors section of Integra's Annual Report on Form 10-K for the year ended December 31, 2006, and information contained in subsequent filings with the Securities and Exchange Commission, could affect actual results.
Source: Integra LifeSciences
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.